<p>Voya Investment Management LLC 在最近向證券交易委員會的披露中表示，其在 Cencora, Inc.（紐約證券交易所代碼：COR - 免費報告）的持股在第三季度減少了 17.7%。該基金在季度內出售了 80,326 股後，持有該公司 373,494 股股票。截至其最近的 SEC 備案，Voya Investment Management LLC 持有的 Cencora 股票約佔 0.19%，價值 116,728,000 美元。</p>
<ul>
<li>在下跌市場中 S&amp;P 500 的前三大贏家</li>
</ul>
<p>其他機構投資者最近也增加或減少了對該公司的持股。Contravisory Investment Management Inc. 在第三季度將其在 Cencora 的持股增加了 1.6%。Contravisory Investment Management Inc. 目前持有 5,469 股該公司股票，價值 1,709,000 美元，在此期間又購買了 87 股。Wedmont Private Capital 在第三季度將其在 Cencora 的持股增加了 11.4%。Wedmont Private Capital 目前持有 2,830 股該公司股票，價值 874,000 美元，在此期間又購買了 289 股。捷克國家銀行在第三季度將其在 Cencora 的持股增加了 16.8%。捷克國家銀行目前持有 49,240 股該公司股票，價值 15,389,000 美元，在上個季度又購買了 7,075 股。Assenagon Asset Management S.A. 在第三季度將其在 Cencora 的持股增加了 915.3%。Assenagon Asset Management S.A. 目前持有 353,021 股該公司股票，價值 110,330,000 美元，在此期間又購買了 318,250 股。最後，Carolina Wealth Advisors LLC 在第三季度將其在 Cencora 的持股增加了 27.9%。Carolina Wealth Advisors LLC 目前持有 6,624 股該公司股票，價值 2,070,000 美元，在上個季度又購買了 1,444 股。目前，97.52% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師觀點</h2>
<p>COR 已成為多份研究報告的主題。TD Cowen 在 11 月 10 日的報告中將 Cencora 的目標價從 350.00 美元上調至 400.00 美元，並給予該股票 &#34;買入&#34; 評級。巴克萊在 12 月 8 日的研究報告中對 Cencora 的股票進行了覆蓋，設定了 &#34;增持&#34; 評級和 400.00 美元的目標價。羅伯特·W·貝爾德在週二的研究報告中為 Cencora 的股票設定了 392.00 美元的目標價。華爾街 Zen 在 11 月 28 日的研究報告中將 Cencora 的股票評級從 &#34;買入&#34; 下調至 &#34;持有&#34;。最後，瑞穗在 11 月 6 日的研究報告中將 Cencora 的目標價從 340.00 美元上調至 380.00 美元，並給予該股票 &#34;跑贏大盤&#34; 評級。一位分析師給予該股票 &#34;強烈買入&#34; 評級，八位分析師給予 &#34;買入&#34; 評級，四位分析師給予 &#34;持有&#34; 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 &#34;適度買入&#34;，平均目標價為 373.25 美元。</p>
<ul>
<li>Walgreens 股票反彈：WBA 可能成為強勁買入的四個理由</li>
</ul>
<p><strong>查看我們關於 Cencora 的最新研究報告</strong></p>
<h2>Cencora 股票表現</h2>
<p>Cencora 股票在週五開盤價為 341.07 美元。該公司的債務與股本比率為 4.32，流動比率為 0.90，速動比率為 0.55。該公司的 50 日移動平均價格為 346.49 美元，200 日移動平均價格為 313.01 美元。該公司的市值為 661.6 億美元，市盈率為 42.90，市盈率增長比率為 1.62，貝塔值為 0.63。Cencora, Inc. 的 12 個月低點為 223.92 美元，12 個月高點為 377.54 美元。</p>
<ul>
<li>Teva Pharma 是參與仿製藥重新崛起的方式</li>
</ul>
<p>Cencora（紐約證券交易所代碼：COR - 獲取免費報告）最近在 11 月 5 日宣佈了其財報。該公司報告季度每股收益為 3.84 美元，超出市場共識預期的 3.79 美元，超出 0.05 美元。Cencora 的股本回報率為 227.15%，淨利潤率為 0.48%。該公司在本季度的收入為 837.3 億美元，而市場共識預期為 833.6 億美元。去年同期，該公司每股收益為 3.34 美元。該公司的收入同比增長了 5.9%。Cencora 已設定其 2026 財年的指導目標為每股收益 17.450-17.75 美元。研究分析師平均預測 Cencora, Inc. 本財年的每股收益為 15.37 美元。</p>
<h2>Cencora 增加股息</h2>
<p>該公司最近還披露了季度股息，已於 12 月 1 日支付。11 月 14 日的股東獲得了每股 0.60 美元的股息。除息日期為 11 月 14 日。這代表着每年 2.40 美元的股息和 0.7% 的收益率。這比 Cencora 之前的季度股息 0.55 美元有所增加。Cencora 的股息支付比率（DPR）目前為 30.19%。</p>
<h2>內部活動</h2>
<p>在其他新聞中，首席執行官 Robert P. Mauch 於 10 月 20 日星期一出售了 5,097 股該股票。該股票以平均價格 326.80 美元出售，總交易額為 1,665,699.60 美元。交易完成後，首席執行官直接持有該公司 37,940 股，價值約 12,398,792 美元。這代表着其持股減少了 11.84%。該交易已在 SEC 的備案中披露，可以通過此鏈接訪問。目前，10.80% 的股票由內部人士持有。</p>
<h2>關於 Cencora</h2>
<p>（免費報告）</p>
<p>Cencora（紐約證券交易所代碼：COR）是一家全球醫療服務和藥品分銷公司，提供跨藥品供應鏈的端到端解決方案。該公司的核心業務包括批發藥品分銷、專科藥品分銷和專科藥房的運營，輔以物流、冷鏈管理和其他旨在支持複雜和温度敏感療法的履行服務。</p>
<p>除了實體分銷，Cencora 還為製藥製造商和醫療服務提供者提供一系列商業和以患者為中心的服務。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Cencora</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>這隻 ETF 在美聯儲降息後獲得了重大助力</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
<li>為什麼除息日對投資者來説重要？</li>
<li>耐克在收益上超出預期，但在中國面臨挑戰並遭遇關税</li>
</ul>
<p><strong>想看看其他對 COR 感興趣的對沖基金持有哪些股票？</strong> 訪問 HoldingsChannel.com，獲取 Cencora, Inc.（NYSE:COR - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 Cencora 1000 美元嗎？</h2>
<p>在考慮 Cencora 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Cencora 並不在名單上。</p>
<p>雖然 Cencora 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Voya Investment Management LLC 在第三季度減少了對 Cencora, Inc. 的持股比例，降幅為 17.7%，目前持有 373,494 股，市值為 1.1673 億美元。其他機構投資者也調整了他們的持倉。分析師對 Cencora 的評級褒貶不一，普遍共識為 “適度買入”，平均目標價為 373.25 美元。Cencora 報告了強勁的盈利和收入增長，並增加了股息。該股票的市值為 661.6 億美元，市盈率為 42.90</p>

<p>Voya Investment Management LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 17.7% during the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 373,494 shares of the company's stock after selling 80,326 shares during the quarter. Voya Investment Management LLC owned about 0.19% of Cencora worth $116,728,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Voya Investment Management LLC 在最近向證券交易委員會的披露中表示，其在 Cencora, Inc.（紐約證券交易所代碼：COR - 免費報告）的持股在第三季度減少了 17.7%。該基金在季度內出售了 80,326 股後，持有該公司 373,494 股股票。截至其最近的 SEC 備案，Voya Investment Management LLC 持有的 Cencora 股票約佔 0.19%，價值 116,728,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市場中 S&amp;P 500 的前三大贏家</li>
</ul>
</div><p>Other institutional investors have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. grew its holdings in Cencora by 1.6% in the third quarter. Contravisory Investment Management Inc. now owns 5,469 shares of the company's stock valued at $1,709,000 after purchasing an additional 87 shares during the period. Wedmont Private Capital grew its stake in shares of Cencora by 11.4% during the 3rd quarter. Wedmont Private Capital now owns 2,830 shares of the company's stock valued at $874,000 after buying an additional 289 shares during the period. Czech National Bank increased its holdings in shares of Cencora by 16.8% during the 3rd quarter. Czech National Bank now owns 49,240 shares of the company's stock worth $15,389,000 after buying an additional 7,075 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of Cencora by 915.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 353,021 shares of the company's stock worth $110,330,000 after buying an additional 318,250 shares during the period. Finally, Carolina Wealth Advisors LLC boosted its holdings in Cencora by 27.9% in the third quarter. Carolina Wealth Advisors LLC now owns 6,624 shares of the company's stock valued at $2,070,000 after acquiring an additional 1,444 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他機構投資者最近也增加或減少了對該公司的持股。Contravisory Investment Management Inc. 在第三季度將其在 Cencora 的持股增加了 1.6%。Contravisory Investment Management Inc. 目前持有 5,469 股該公司股票，價值 1,709,000 美元，在此期間又購買了 87 股。Wedmont Private Capital 在第三季度將其在 Cencora 的持股增加了 11.4%。Wedmont Private Capital 目前持有 2,830 股該公司股票，價值 874,000 美元，在此期間又購買了 289 股。捷克國家銀行在第三季度將其在 Cencora 的持股增加了 16.8%。捷克國家銀行目前持有 49,240 股該公司股票，價值 15,389,000 美元，在上個季度又購買了 7,075 股。Assenagon Asset Management S.A. 在第三季度將其在 Cencora 的持股增加了 915.3%。Assenagon Asset Management S.A. 目前持有 353,021 股該公司股票，價值 110,330,000 美元，在此期間又購買了 318,250 股。最後，Carolina Wealth Advisors LLC 在第三季度將其在 Cencora 的持股增加了 27.9%。Carolina Wealth Advisors LLC 目前持有 6,624 股該公司股票，價值 2,070,000 美元，在上個季度又購買了 1,444 股。目前，97.52% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>COR has been the topic of a number of research reports. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, November 10th. Barclays initiated coverage on shares of Cencora in a research report on Monday, December 8th. They set an &#34;overweight&#34; rating and a $400.00 target price for the company. Robert W. Baird set a $392.00 price objective on shares of Cencora in a research report on Tuesday. Wall Street Zen downgraded shares of Cencora from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, November 28th. Finally, Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $373.25.</p>
<div class="lb-trans"><p>COR 已成為多份研究報告的主題。TD Cowen 在 11 月 10 日的報告中將 Cencora 的目標價從 350.00 美元上調至 400.00 美元，並給予該股票 &#34;買入&#34; 評級。巴克萊在 12 月 8 日的研究報告中對 Cencora 的股票進行了覆蓋，設定了 &#34;增持&#34; 評級和 400.00 美元的目標價。羅伯特·W·貝爾德在週二的研究報告中為 Cencora 的股票設定了 392.00 美元的目標價。華爾街 Zen 在 11 月 28 日的研究報告中將 Cencora 的股票評級從 &#34;買入&#34; 下調至 &#34;持有&#34;。最後，瑞穗在 11 月 6 日的研究報告中將 Cencora 的目標價從 340.00 美元上調至 380.00 美元，並給予該股票 &#34;跑贏大盤&#34; 評級。一位分析師給予該股票 &#34;強烈買入&#34; 評級，八位分析師給予 &#34;買入&#34; 評級，四位分析師給予 &#34;持有&#34; 評級。根據 MarketBeat.com 的數據，該公司的平均評級為 &#34;適度買入&#34;，平均目標價為 373.25 美元。</p>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票反彈：WBA 可能成為強勁買入的四個理由</li>
</ul>
</div><p><strong>View Our Latest Research Report on Cencora</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Cencora 的最新研究報告</strong></p>
</div><h2>Cencora Stock Performance</h2>
<div class="lb-trans"><h2>Cencora 股票表現</h2>
</div><p>Cencora stock opened at $341.07 on Friday. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm's fifty day moving average price is $346.49 and its 200 day moving average price is $313.01. The company has a market capitalization of $66.16 billion, a price-to-earnings ratio of 42.90, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54.</p>
<div class="lb-trans"><p>Cencora 股票在週五開盤價為 341.07 美元。該公司的債務與股本比率為 4.32，流動比率為 0.90，速動比率為 0.55。該公司的 50 日移動平均價格為 346.49 美元，200 日移動平均價格為 313.01 美元。該公司的市值為 661.6 億美元，市盈率為 42.90，市盈率增長比率為 1.62，貝塔值為 0.63。Cencora, Inc. 的 12 個月低點為 223.92 美元，12 個月高點為 377.54 美元。</p>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是參與仿製藥重新崛起的方式</li>
</ul>
</div><p>Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the firm earned $3.34 earnings per share. The company's revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cencora（紐約證券交易所代碼：COR - 獲取免費報告）最近在 11 月 5 日宣佈了其財報。該公司報告季度每股收益為 3.84 美元，超出市場共識預期的 3.79 美元，超出 0.05 美元。Cencora 的股本回報率為 227.15%，淨利潤率為 0.48%。該公司在本季度的收入為 837.3 億美元，而市場共識預期為 833.6 億美元。去年同期，該公司每股收益為 3.34 美元。該公司的收入同比增長了 5.9%。Cencora 已設定其 2026 財年的指導目標為每股收益 17.450-17.75 美元。研究分析師平均預測 Cencora, Inc. 本財年的每股收益為 15.37 美元。</p>
</div><h2>Cencora Increases Dividend</h2>
<div class="lb-trans"><h2>Cencora 增加股息</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora's previous quarterly dividend of $0.55. Cencora's dividend payout ratio (DPR) is presently 30.19%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，已於 12 月 1 日支付。11 月 14 日的股東獲得了每股 0.60 美元的股息。除息日期為 11 月 14 日。這代表着每年 2.40 美元的股息和 0.7% 的收益率。這比 Cencora 之前的季度股息 0.55 美元有所增加。Cencora 的股息支付比率（DPR）目前為 30.19%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.80% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 Robert P. Mauch 於 10 月 20 日星期一出售了 5,097 股該股票。該股票以平均價格 326.80 美元出售，總交易額為 1,665,699.60 美元。交易完成後，首席執行官直接持有該公司 37,940 股，價值約 12,398,792 美元。這代表着其持股減少了 11.84%。該交易已在 SEC 的備案中披露，可以通過此鏈接訪問。目前，10.80% 的股票由內部人士持有。</p>
</div><h2>About Cencora</h2>
<div class="lb-trans"><h2>關於 Cencora</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.</p>
<div class="lb-trans"><p>Cencora（紐約證券交易所代碼：COR）是一家全球醫療服務和藥品分銷公司，提供跨藥品供應鏈的端到端解決方案。該公司的核心業務包括批發藥品分銷、專科藥品分銷和專科藥房的運營，輔以物流、冷鏈管理和其他旨在支持複雜和温度敏感療法的履行服務。</p>
</div><p>Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.</p>
<div class="lb-trans"><p>除了實體分銷，Cencora 還為製藥製造商和醫療服務提供者提供一系列商業和以患者為中心的服務。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
<li>What is MarketRank™? How to Use it</li>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Cencora</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>這隻 ETF 在美聯儲降息後獲得了重大助力</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
<li>為什麼除息日對投資者來説重要？</li>
<li>耐克在收益上超出預期，但在中國面臨挑戰並遭遇關税</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding COR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 COR 感興趣的對沖基金持有哪些股票？</strong> 訪問 HoldingsChannel.com，獲取 Cencora, Inc.（NYSE:COR - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 Cencora 1000 美元嗎？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Cencora 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Cencora 並不在名單上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cencora 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Voya Investment Management LLC 減少了其在 Cencora, Inc. $COR 的持倉